SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Intuitive Surgical, Inc. (ISRG)
ISRG 586.16+0.2%Jan 9 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
lightshipsailor
From: IceHawk4/17/2018 7:34:37 PM
1 Recommendation   of 438
 
Intuitive Surgical Pops After Crushing First-Quarter Expectations

Intuitive Surgical ( ISRG) popped late Tuesday after crushing Wall Street's first-quarter expectations on growing demand for its robotic surgical system called da Vinci.

Shares spiked 5.9%, near 460, in after-hours trading on the stock market today. The stock ended the regular session up 4.1%, at 435.45. Intuitive stock is consolidating with a buy point at 452.10. Meanwhile, medical products stocks broadly rose 1.6% at the closing bell.

For the first quarter, Intuitive reported adjusted profit of $2.44 per share on $848 million in revenue, growing 43% and 25%, respectively, vs. the year-earlier period. Both metrics easily topped the consensus for adjusted income of $1.99 per share on $767 million in sales.

Evercore analyst Vijay Kumar notes Intuitive was expected to report a solid quarter — "and the company did not disappoint."

"This impressive top line was mostly driven by systems (sales), which contributed two-thirds to the revenue beat with systems coming in about 33 above consensus," Kumar said in a note to clients. "The remaining one-third beat came from higher instruments and accessories consumable revenue."

System Sales RiseWorldwide, Intuitive shipped 185 da Vinci Surgical Systems, up from 133 in the year-earlier quarter. The number of procedures performed using da Vinci systems grew 15% on a year-over-year basis, driven by growth in surgical and urologic procedures.

The lion's share of growth stemmed from system sales, which increased 46% to $253 million. But the biggest chunk of sales came from instrument and accessory revenue, which grew 21% to $460 million. Service revenue also rose 11% to $153 million.

Instrument and accessory revenue per procedure came in at $1,935, which is seasonally strong, Kumar said. The number of procedures in the U.S. grew 14%, though international sales dipped 20%. Investors will likely look for updates on the system's performance in China and Japan, he said.

Intuitive didn't offer 2018 guidance. Analysts had modeled adjusted profit of $9.61 per share on $3.49 billion in sales.

ALLISON GATLIN
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext